Resources from the same session
Welcome and introduction
Presenter: Zofia Piotrowska
Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations
Resources:
Webcast
Molecular Reports in advanced NSCLC: How to optimise report structure, molecular tumour board input and actionability
Presenter: Ales Ryska
Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations
Resources:
Slides
Webcast
Optimal therapeutic regimens for advanced NSCLC patients with rare oncogenic translocations (beyond ALK) and insights on resistance upon retesting
Presenter: Zofia Piotrowska
Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations
Resources:
Slides
Webcast
Q&A and discussion
Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations
Resources:
Webcast
Concluding remarks
Presenter: Antonio Calles Blanco
Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations
Resources:
Webcast